Target intelligence / Profile preview

Appetite regulation via increased satiety

01

Overview

Appetite regulation via increased satiety is a multifaceted neurohormonal process centered in the hypothalamus, particularly the arcuate nucleus, where signals from gut hormones like ghrelin, cholecystokinin (CCK), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1) integrate with adipose-derived leptin to balance hunger and fullness.[1][2][3] Ghrelin promotes hunger by activating growth hormone secretagogue receptor (GHSR-1a) and AgRP/NPY neurons, while satiety is enhanced by leptin binding to LepR receptors, stimulating pro-opiomelanocortin (POMC) neurons to release alpha-MSH, which acts on melanocortin receptors (MC3R/MC4R) to suppress appetite and boost energy expenditure.[1][3] Vagal afferents from the gut relay mechanical (distension) and chemical (hormone) cues to the nucleus tractus solitarius (NTS), further propagating satiety to hypothalamic regions like the paraventricular nucleus.[2] Dysregulation contributes to obesity through leptin resistance or imbalanced ghrelin-leptin ratios, disrupting energy homeostasis.[1][2] Therapeutically, GLP-1 receptor agonists mimic satiety signals to reduce food intake, though challenges include peripheral side effects and incomplete central penetration.[2][3]

02

Mechanism of action

Activation of satiety signals via hormones like leptin on LepR receptors in hypothalamus, stimulating POMC neurons and inhibiting AgRP/NPY neurons; Gut hormone effects (e.g., GLP-1, PYY, CCK) relaying fullness to brainstem and hypothalamus via vagal afferents

03

Biological functions

Regulation of hunger and satiety signals via hypothalamic integrationEnergy homeostasis through hormonal feedback from gut and adipose tissueInhibition of food intake and promotion of fullness
04

Disease associations

Obesity (dysregulation leads to imbalance in energy intake)Metabolic disorders (e.g., insulin resistance from altered signaling)
05

Safety considerations

Leptin resistance in obesity, reducing efficacy of satiety signalingPotential for gastrointestinal side effects with GLP-1 agonists (e.g., nausea from enhanced satiety)Dysregulation leading to hyperphagia or altered energy expenditure
06

Interacting drugs

GLP-1 receptor agonists (e.g., liraglutide, which suppress appetite via satiety pathways)
07

Biomarkers

Plasma leptin levels (indicate adipose energy stores and satiety signaling)Ghrelin levels (inverse to satiety, rise pre-meal)GLP-1, PYY, CCK (postprandial satiety markers)

Beyond the preview

Go deeper on Appetite regulation via increased satiety.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Appetite regulation via increased satiety.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call